Abstract: A method and apparatus for controlling a fuel-fired appliance is provided. The appliance enters a wait state in which burner operation ceases if a sensor indicates the presence of flammable vapors that are above an acceptable and/or safe vapor level. The appliance returns to a run state if the vapor level returns to an acceptable and/or safe vapor level within a period of time, but enters a lockout state if the vapor level does not return to an acceptable and/or safe vapor level within the period of time.

Abstract: Appliance control with ground reference compensation is provided. Ground reference compensation can be desirable when a device or component of an appliance is powered by a higher power source, and is controlled by a controller that is powered by a lower power source. In such a situation, a voltage difference can develop between the ground references of the higher and lower power sources, which can affect accurate control of the device or component. In some cases, a measure related to the voltage difference between the ground references is first determined, and then the power/voltage that is ultimately delivered to the device or component is adjusted or compensated based, at least in part, on the determined difference.

Abstract: Appliance control with ground reference compensation is provided. Ground reference compensation can be desirable when a device or component of an appliance is powered by a higher power source, and is controlled by a controller that is powered by a lower power source. In such a situation, a voltage difference can develop between the ground references of the higher and lower power sources, which can affect accurate control of the device or component. In some cases, a measure related to the voltage difference between the ground references is first determined, and then the power/voltage that is ultimately delivered to the device or component is adjusted or compensated based, at least in part, on the determined difference.

Abstract: Vapor sensing systems and methods are disclosed. An appliance such as a gas water heater, clothes dryer, and the like can be associated with a controller for controlling the appliance. A vapor sensor is also associated with the appliance, such that the vapor sensor comprises an active sensor and an error sensor, wherein the active sensor generates an active signal and the error sensor generates an error signal. An amplifier is also associated with the vapor sensor, such that the amplifier subtracts the error signal from the active signal to generate a compensated signal indicative of the presence of an ignitable vapor within a vicinity of the appliance and thereby instruct the controller to shut down the appliance.

Abstract: A system and method for placing advertisements with media organizations comprising making use of an electronic database; advertisers accessing the database so as to place offers for an advertising campaign in the data base; media users associated with a media organization accessing the database so as to review the offers; the media user accepting or declining the offers; placing orders for advertising specified by the campaign if an offer is accepted; determining when the advertisements have been run; and transferring funds from the advertisers to the media organization when the advertisements have been run. An electronic message such as an electronic affidavit is provided to the advertiser when the advertisement has been run.

Abstract: Cytotoxic biotherapeutic agents effective for treating certain types of cancer in humans are provided which comprise the TP-3 murine monoclonal antibody chemically conjugated to pokeweed antiviral protein (PAP). The invention further provides a method which utilizes the disclosed cytotoxic biotherapeutic agents to systemically treat cancer patients. With slight modifications the method of the present invention should be generally applicable to preparation and use of other cytotoxic biotherapeutic agents using chemical or recombinant derivatives of the TP-3 or TP-1 antibodies or PAP toxin. The invention is applicable to cancer patients who express the p80 antigen recognized by the TP-1/TP-3 antibodies either on the surface of their tumor cells or on the tumor blood vessels.

Abstract: The present invention provides a liposome comprising an effective immunoadjuvant amount of a lymphokine such as IL-2. Also provided is an effective antineoplastic amount of IL-2 liposomes in combination with adoptively transferred cells stimulated with anti-CD3 monoclonal antibody plus IL-2.

Abstract: Cytotoxic biotherapeutic agents effective for treating certain types of cancer in humans are provided which comprise the TP-3 murine monoclonal antibody chemically conjugated to pokeweed antiviral protein (PAP). The invention further provides a method which utilizes the disclosed cytotoxic biotherapeutic agents to systemically treat cancer patients. With slight modifications the method of the present invention should be generally applicable to preparation and use of other cytotoxic biotherapeutic agents using chemical or recombinant derivatives of the TP-3 or TP-1 antibodies or PAP toxin. The invention is applicable to cancer patients who express the p80 antigen recognized by the TP-1/TP-3 antibodies either on the surface of their tumor cells or on the tumor blood vessels.

Abstract: The present invention provides a liposome comprising an effective immunoadjuvant amount of a lymphokine such as IL-2. Also provided is an effective antineoplastic amount of IL-2 liposomes in combination with adoptively transferred cells stimulated with anti-CD3 monoclonal antibody plus IL-2.

Abstract: Glutamine is administered orally at a rate of about 4.5 g/m.sup.2 per day to treat oropharyngeal mucositis. This is administered to patients that experience or may develop oropharyngeal mucositis, especially those caused by chemotherapy or radiotherapy.

Abstract: Glutamine is administered orally at a rate of about 4.5 g/m.sup.2 per day to treat oropharyngeal mucositis. This is administered to patients that experience or may develop oropharyngeal mucositis, especially those caused by chemotherapy or radiotherapy.

Abstract: The present invention provides a liposome comprising an effective immunoadjuvant amount of a lymphokine such as IL-2. Also provided is an effective antineoplastic amount of IL-2 liposomes in combination with adoptively transferred cells stimulated with anti-CD3 monoclonal antibody plus IL-2.

Abstract: Glutamine is administered orally at a rate of about 4.5 g/m2 per day to treat oropharyngeal mucositis. This is administered to patients that experience or may develop oropharyngeal mucositis, especially those caused by chemotherapy or radiotherapy.